Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Andrzej Niemierko, Ph.D.

Co-Author

This page shows the publications co-authored by Andrzej Niemierko and Anthony Zietman.
Connection Strength

1.018
  1. Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade. Cancer Med. 2017 Jul; 6(7):1827-1836.
    View in: PubMed
    Score: 0.178
  2. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012 Apr; 61(4):705-11.
    View in: PubMed
    Score: 0.121
  3. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA. 2010 Mar 17; 303(11):1046-53.
    View in: PubMed
    Score: 0.108
  4. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncol. 2018 05 10; 4(5):e175230.
    View in: PubMed
    Score: 0.048
  5. Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. Pract Radiat Oncol. 2018 May - Jun; 8(3):206-212.
    View in: PubMed
    Score: 0.046
  6. Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. J Urol. 2018 02; 199(2):407-415.
    View in: PubMed
    Score: 0.045
  7. Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience. Clin Genitourin Cancer. 2017 Aug 03.
    View in: PubMed
    Score: 0.045
  8. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 06; 71(6):952-960.
    View in: PubMed
    Score: 0.043
  9. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol. 2017 07; 72(1):54-60.
    View in: PubMed
    Score: 0.043
  10. Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. Pract Radiat Oncol. 2017 Mar - Apr; 7(2):e125-e133.
    View in: PubMed
    Score: 0.043
  11. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1028-1036.
    View in: PubMed
    Score: 0.042
  12. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2014 Mar 01; 88(3):618-23.
    View in: PubMed
    Score: 0.035
  13. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72.
    View in: PubMed
    Score: 0.035
  14. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):311-6.
    View in: PubMed
    Score: 0.033
  15. Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55.
    View in: PubMed
    Score: 0.033
  16. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6.
    View in: PubMed
    Score: 0.032
  17. Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. Radiother Oncol. 2012 Apr; 103(1):12-7.
    View in: PubMed
    Score: 0.031
  18. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Feb 01; 82(2):e201-9.
    View in: PubMed
    Score: 0.029
  19. Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1095-103.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.